About: From micro to nano: evolution and impact of drug delivery in treating disease

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: From micro to nano: evolution and impact of drug delivery in treating disease Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	From micro to nano: evolution and impact of drug delivery in treating disease
Creator	Langer, Robert Hrkach, Jeff
Source	Medline; PMC
abstract	Over the past 50 years, drug delivery breakthroughs have enabled the approval of several important medicines. Often, this path starts with innovation from academic collaborations amongst biologists, chemists, and engineers, followed by the formation of a start-up company driving clinical translation and approval. An early wave featured injectable (i.e., intramuscular, subcutaneous) biodegradable polymeric microspheres to control drug release profiles for peptides and small molecules (e.g., Lupron Depot®, Risperdal Consta®). With these early successes for microspheres, research shifted to exploring systemic delivery by intravenous injection, which required smaller particle sizes and modified surface properties (e.g., PEGylation) to enable long circulation times. These new innovations resulted in the nanoparticle medicines Doxil® and Abraxane®, designed to improve the therapeutic index of cytotoxic cancer agents by decreasing systemic exposure and delivering more drug to tumors. Very recently, the first siRNA lipid nanoparticle medicine, Patisiran (Onpattro®), was approved for treating hereditary transthyretin-mediated amyloidosis. In this inspirational note, we will highlight the technological evolution of drug delivery from micro- to nano-, citing some of the approved medicines demonstrating the significant impact of the drug delivery field in treating many diseases.
has issue date	2020-05-08(xsd:dateTime)
bibo:doi	10.1007/s13346-020-00769-6
bibo:pmid	32385828
has license	no-cc
sha1sum (hex)	6cfbececcc39265c22b03f5d7b0a7a4c50cf834f
schema:url	https://doi.org/10.1007/s13346-020-00769-6
resource representing a document's title	From micro to nano: evolution and impact of drug delivery in treating disease
has PubMed Central identifier	PMC7209970
has PubMed identifier	32385828
schema:publication	Drug Deliv Transl Res
resource representing a document's body	covid:6cfbececcc39265c22b03f5d7b0a7a4c50cf834f#body_text
is schema:about of	named entity 'innovation' named entity 'particle sizes' named entity 'academic' named entity 'medicines' named entity 'SHIFTED' named entity 'TRANSLATION' named entity 'MODIFIED' named entity 'CYTOTOXIC' named entity 'COMPANY' named entity 'agents' named entity 'early' named entity 'subcutaneous' named entity 'highlight' named entity 'nanoparticle' named entity 'Endosomal' named entity 'pharmacokinetic profile' named entity 'drug delivery' named entity 'times' named entity 'drug delivery' named entity 'nanoparticle' named entity 'microspheres' named entity 'microspheres' named entity 'therapeutic index' named entity 'Risperdal' named entity 'clinical translation' named entity 'cytotoxic' named entity 'biodegradable' named entity 'tumors' named entity 'small molecules' named entity 'evolution' named entity 'long' named entity 'Very' named entity 'upper airways' named entity 'lipid' named entity 'Lupron' named entity 'albumin' named entity 'biotechnology' named entity 'gene' named entity 'preclinical models' named entity 'non-small cell lung' named entity 'macromolecules' named entity 'RNA interference' named entity 'prostate cancer' named entity 'PLG' named entity 'acetate' named entity 'potency' named entity 'PLG' named entity 'polyneuropathies' named entity 'biological systems' named entity 'protein expression' named entity 'halflife' named entity 'drug molecule' named entity 'drug delivery' named entity 'mRNA' named entity 'pharmacokinetic profile' named entity 'gonadotropin-releasing hormone' named entity 'Nutropin' named entity 'biopharmaceutical' named entity 'therapeutic agent' named entity 'systemic administration' named entity 'liposomes' named entity 'microsphere' named entity 'nanoparticles' named entity 'cardiovascular' named entity 'permeability' named entity 'Patisiran' named entity 'vaccines' named entity 'risperidone' named entity 'Robert S. Langer' named entity 'nanomedicine' named entity 'drug delivery systems' named entity 'PEGylated' named entity 'NIH' named entity 'clinical study' named entity 'March 16, 2020' named entity 'PLG' named entity 'doxorubicin' named entity 'Springer Nature' named entity 'macromolecules' named entity 'microsphere'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software